Search Results 2791-2800 of 18235 for rheumatoid arthritis

  1. Publications - Mark J. Truty, M.D., M.S. - Mayo Clinic

    Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma. Ann Surg Oncol. 2024 Oct ...

  2. Biological Therapy For Cancer Clinical Trials - Mayo Clinic Research

    ... factor receptor 2 (HER2)-negative, unresectable, locally advanced and ... factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally ...

  3. Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease - Mayo Clinic

    Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.). Subjects on full-dose ...

  4. Publications - Fernanda Bellolio, M.D., M.S. - Mayo Clinic

    ... factor Xa inhibitor-associated gastrointestinal bleeding. Am J Emerg Med. 2023 Nov; 73:1-6 Epub 2023 July 24. View PubMed; Stanich J, Sunga K, Loprinzi-Brauer ...

  5. A Study to Evaluate the Safety and Tolerability of TreT in Subjects with PAH Currently Using Tyvaso - Mayo Clinic

    Subject has a musculoskeletal disorder (eg, arthritis affecting the lower limbs, recent hip or knee joint replacement) or any disease that would likely be ...

  6. ATHN 11: A Study of Liver Transplantation Outcomes - Mayo Clinic

    ... factor. Patients with undetectable versus detectable HCV RNA had a survival probability of 80% versus 39% at 1 year and 80% versus 30% at 3 and 5 years (p ...

  7. Carpal tunnel syndrome - Doctors and departments - Mayo Clinic

    ... arthritis, Scaphoid fracture, Distal radius fracture, Scaphoid nonunion. Show more areas of focus for Alexander Y. Shin, M.D.. Research. Publications. See a ...

  8. Clinical trials - Oncology (Medical)

    Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements ...

  9. Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients with Myelofibrosis - Mayo Clinic

    ... factor treatment (e.g., erythropoietin), hormones (e.g., androgens, danazol) ≤ 14 days prior to registration; note: patients who are on ruxolitinib may ...

  10. Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer - Mayo Clinic

    ... factor receptor 2 (HER2) status and radiographic evidence of distant metastatic disease; Measurable disease; Head and neck cancer OR metastatic breast for ...